Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Psoriasis 1Periodic Fevers Syndrome 1Arthritis, Rheumatoid 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × secukinumab × Clear all
NCT01961609 2019-03-18

SIGNATURE

Novartis

Phase 3 Completed
235 enrolled 23 charts

Psoriasis

NCT02911857 2018-08-20

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Novartis

Phase 3 Completed
4 enrolled 7 charts

Periodic Fevers Syndrome

NCT01350804 2016-05-23

NURTURE 1

Novartis

Phase 3 Completed
551 enrolled 19 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡